This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: Rukundo Ntaganda: Innovator in Pharmaceutical Research
Introduction
Rukundo Ntaganda is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target specific diseases.
Latest Patents
Ntaganda holds a patent for "Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors." This patent describes a compound of Formula (I), or a pharmaceutically acceptable salt thereof, which has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder. The details of Formula (I) include specific definitions for R through R, as outlined in the patent documentation. He has 1 patent to his name.
Career Highlights
Rukundo Ntaganda is currently associated with Novartis AG, a leading global healthcare company. His work focuses on innovative solutions that address complex medical challenges. His research has the potential to impact the treatment of various diseases significantly.
Collaborations
Ntaganda has collaborated with esteemed colleagues, including Christopher Adair and Katsumasa Nakajima. These partnerships enhance the research and development process, fostering innovation in the pharmaceutical industry.
Conclusion
Rukundo Ntaganda is a prominent figure in pharmaceutical innovation, with a focus on developing effective treatments for serious medical conditions. His contributions and collaborations continue to advance the field and improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile